Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Polycystic Ovary Syndrome 2Neoplasms 2Urinary Bladder Neoplasms 1Stage I Prostate Adenocarcinoma 1Prostatic Neoplasms 1Osteoporosis 1Infertility 1Endometrial Neoplasms 1Diarrhea 1Cardiovascular Diseases 1Brain Neoplasms 1Anovulation 1

Interventions

Cholecalciferol 4Nutrition Assessment 3Exercise 3Blood Pressure 3Atorvastatin 3acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Vitamin E 2Vitamin D 2Rosuvastatin Calcium 2Methods 2Metformin 2Gonadotropin-Releasing Hormone 2Geritol 2Fish Oils 2Fatty Acids, Omega-3 2Ethanol 2Educational Status 2Diet, Mediterranean 2Aspirin 2xinmailong 1sofosbuvir-velpatasvir drug combination 1pembrolizumab 1palbociclib 1ficlatuzumab 1beta Carotene 1amlodipine, atorvastatin drug combination 1Vorinostat 1Vitamin B 6 1Vitamin B 12 1Tumor Necrosis Factor Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cardiovascular Diseases × Raloxifene Hydrochloride × Clear all
NCT00190593 2007-01-26

Raloxifene Use for The Heart

Eli Lilly and Company

Phase 3 Completed
10,000 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡